Active, not recruitingPHASE1, PHASE2NCT06392009
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
Studying Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GRIN Therapeutics, Inc.
- Intervention
- Radiprodil(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (20)
- Queensland Children Hospital, South Brisbane, Australia
- Universitair Ziekenhuis Antwerpen (UZA), Antwerp, Belgium
- University Hospitals Leuven, Pediatric Neurology, Leuven, Belgium
- Alberta Children's Hospital, Calgary, Canada
- The Hospital for Sick Children (Sick Kids), Toronto, Canada
- BC Children's Hospital, Vancouver, Canada
- IRCCS Istituto Giannina Gaslini, Genoa, Liguria, Italy
- AOU Meyer, Florence, Tuscany, Italy
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Roma, Italy
- Universita Cattolica del Sacro Cuore - Policlinico Universitario "Agostino Gemelli", Roma, Italy
- UMC Uthrecht - Wilhelmina Kinderziekenhuis, Utrecht, Netherlands
- Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
- Centrum Medyczne Plejady, Krakow, Poland
- Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Poland
- Instytut Pomnik - Centrum Zdrowia Dziecka, Warsaw, Poland
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06392009 on ClinicalTrials.govOther trials for Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07561957A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) GuidelinesSt. James's Hospital, Ireland
- RECRUITINGPHASE1NCT07369505Sapu003 in Advanced mTOR-sensitive Solid TumorsSAPU NANO (US) LLC
- ACTIVE NOT RECRUITINGNCT02461459Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)Boston Children's Hospital
See all trials for Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis →